PAVmed Inc. Cash Flow Statement
PAVM|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
PAVmed Inc. used $34M in operating cash flow and negative free cash flow of $34M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | $39.8M | -$64.2M | -$89.0M | -$50.3M | -$34.3M |
| Depreciation & Amortization | $1.2M | $2.9M | $2.5M | $226.0K | $23.0K |
| Operating Cash Flow | -$33.6M | -$52.0M | -$71.0M | -$40.6M | -$21.9M |
| Capital Expenditures | $55.0K | $242.0K | $1.5M | $1.5M | $55.0K |
| Free Cash Flow | -$33.6M | -$52.3M | -$72.5M | -$42.1M | -$22.0M |
| FCF Margin | -1122.2% | -1742.6% | -2901.0% | -8412.0% | -4393.8% |